文献速递前列腺癌

每两周一次卡巴他赛治疗转移性去势抵抗性前列腺癌的安全性与疗效

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
PubMed 文献 · BJU Int · 2017-04-27

这项前瞻性先导研究于2013年10月至2016年2月纳入43例转移性去势抵抗性前列腺癌患者,给予卡巴他赛16 mg/m²(4周周期第1天和第15天)联合预防性粒细胞集落刺激因子。3级及以上毒性包括乏力16.3%、中性粒细胞减少11.6%等,52.4%患者PSA下降≥30%,中位总生存15.2个月。作者认为该方案毒性可控,计划开展III期试验与标准方案比较。

要点

  • 卡巴他赛16 mg/m²每两周给药联合G-CSF,3级及以上乏力16.3%、中性粒细胞减少11.6%。
  • 52.4%患者PSA下降≥30%,40.5%下降≥50%,中位总生存15.2个月。
  • 作者认为该方案在多西他赛和阿比特龙醋酸酯经治患者中毒性可控。

核心结论

  • 这项前瞻性先导研究提示,卡巴他赛16 mg/m²每两周给药在多西他赛和阿比特龙醋酸酯经治的mCRPC患者中毒性可控。
  • 计划开展前瞻性III期试验,将该方案与标准卡巴他赛方案比较以确认结果。

研究设计与样本

  • 前瞻性先导研究,2013年10月至2016年2月纳入43例mCRPC患者。
  • 卡巴他赛16 mg/m²,4周周期第1天和第15天给药,联合预防性粒细胞集落刺激因子(G-CSF)。
  • 分析安全性及疗效(PSA反应、生物学/临床/影像学无进展生存和总生存)。

主要发现

  • 所有患者均接受过多西他赛,79.1%接受过阿比特龙醋酸酯。
  • 入组时46.5%年龄>70岁,27.9%东部肿瘤协作组体能状态评分≥2。
  • 6例因毒性停止治疗。
  • 3级及以上毒性:乏力16.3%、中性粒细胞减少11.6%、血小板减少9.3%、腹泻7%、贫血4.7%、发热性中性粒细胞减少4.7%、血尿2.3%。
  • 52.4%达到PSA下降≥30%,40.5%达到PSA下降≥50%;中位总生存15.2个月。

关键数值与推荐

  • 卡巴他赛剂量16 mg/m²,4周周期第1天和第15天给药,联合预防性G-CSF。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the safety and efficacy of a 2-weekly cabazitaxel schedule in patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: During the period October 2013 to February 2016, 43 patients with mCRPC were treated with cabazitaxel (16 mg/m2 , on days 1 and 15 of a 4-week cycle) together with prophylactic granulocyte colony-stimulating factor (G-CSF). The safety profile and efficacy (prostate-specific antigen [PSA] response; biological, clinical or radiological progression-free survival [PFS] and overall survival [OS]) of the treatment were analysed. RESULTS: All patients had received prior docetaxel and 79.1% abiraterone acetate. At inclusion, 46.5% were aged >70 years and 27.9% had an Eastern Cooperative Oncology Group performance status ≥2. Six patients stopped treatment because of toxicity. Grade ≥3 toxicities were: asthenia (16.3%); neutropenia (11.6%); thrombocytopenia (9.3%); diarrhoea (7%), anaemia (4.7%), febrile neutropenia (4.7%) and haematuria (2.3%). In all, 52.4% achieved a ≥30% PSA response and 40.5% had a ≥50% PSA response. The median OS was 15.2 months. CONCLUSION: This prospective pilot study suggests that cabazitaxel 16 mg/m² given 2-weekly has a manageable toxicity profile in docetaxel- and abiraterone acetate-pretreated patients with mCRPC. A prospective phase III trial comparing this regimen with the standard cabazitaxel regimen is planned to confirm these results.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Clément-Zhao A, Auvray M, Aboudagga H, et al. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. BJU Int. 2017. PMID: 28370882. doi:10.1111/bju.13855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。